An expanded access record providing Vidutolimod in Refractory Melanoma, sponsored by Regeneron Pharmaceuticals. No longer available. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Regeneron Pharmaceuticals · Expanded access
Provide Compassionate Use of Vidutolimob
Compassionate use is only available to patients who transitioned from a previous vidutolimod (CMP-001) study.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
Browse Melanoma studies →Regeneron Pharmaceuticals is the lead sponsor of 400 studies on the registry; 91 are open to participants now.
Of its 120 completed or terminated interventional studies of FDA-regulated products, 77 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
-
Exclusion Criteria:
-
Also known as: CMP-001
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regeneron Pharmaceuticals